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IXE have reported in our preceding communication (Csaba, Horva'th and
Acs. 1960) that the components of heparin shorten the life of tumour-bearing
animals by promoting neoplastic growth. Since, according to the literature,
these substances may be synthesized by the tumours themselves (Kizer and
McCoy, 1959) and siiice-on the other hand-they accumulate in the serum
of individuals with advanced tumours (Almquist and Lansing, 1957 ; Rottimer,
Levy and Conte, 1958 ; Shetlar et al., 1949 ; Weimer et al., 1957 ; Winzler and
Smyth, 1948), we thought it justified to ascertain whether and if so how the
neutralization of these substances would affect the vitality of tumours. In accor-
dance with our programme, described in the preceding communication, we
neutralized the heparinoid substances in two kinds of experiments : in tissue
cultures and in the living organism itself.
METHOD
In vitro experiments to test heparin inhibitors were performed in 600 tissue
cultures, half of which were Maximow's double cover slip cultures and the other
half flat-tube cultures (T6r6, 1959). Fowl plasma coagulated with chick embryo
extract, to which no heparinoid had been added, served as protective medium.
A mixture of horse serum, chick embryo extract and Tyrode solution (3: 1: 6)
was employed as culture medium for the controls. Toluidine blue was used as
heparin inhibitor in the experimental cultures, this being added to the liquid
medium to give a concentration of I y/ml. or 10y/ml. (cal-led
" final concen-
tration
" in the following). It was either immediately or 48 hours after explan-
tation that the washing fluid containing toluidine blue was added to the cultures.
We observed the cultures during 10 days or fixed them within this period. The
test cultures were obtained fromC3H, Gue'rin, Yoshida and Ehrlich tumours,
while the control cultures were derived from the thymus, liver, spleen, lymph
node, kidney, adrenal, brain, lung and heart of 16-17-day-old rat embryo's and
also of 3-day-old rats.
In vivo experiments to test heparin inhibitors were performed on 186 mice and
72 rats. The former were taken from the registered white and sand-coloured
stock of the National Institute of Public Health, the latter from our own stock.
Gue'rin, Yoshida, Ehrlich ascites and Crocker S. 180 tumours weretransplanted.
As inhibitory substances, protamine-sulphate injection I per cent (Roche),
toluidine blue (Gurr and Schuchard), thionine (Griibler), mixtures of the aboveI
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and, ammonium chloride (United Works ofPharmaceutical and Dietetic Products,
Budapest) were applied.
At the outset, toluidine blue alone was used for the purposes of inhibition.
It was first added to the food of the animals in a pulverized form. It was not well
tolerated and the dose applied could not be estimated accurately. Therefore, we
tried to administer the dyeby way of agastric tube. The technique ofadministra-
tion was rather unsatisfactory and quite a number of the animals died during the
process of intubation which explains why there are certain groups in the tables
with such a low number of test animals.
Having been convinced by the results of our preliminary experiments that,
neither toluidine blue nor protamine sulphate alone were adequately efficient if
given in tolerated doses, we had to start combined treatments. The tested com-
binations are denoted by the character
" T ", i.e. the first letter of toluidine blue,
their chiefingredient. The combined preparations bear the numbers T, to Tll,
of which only T5, T4 and-to a lesser extent-Tll proved to be useful tumour
inhibitors.
ThepreparationT5contains IOmg./ml. o'ftoluidineblueandprotaminesulphate.
Rats weregiven I0 mg./I00 g. bodyweight oftoluidine blue and 0-5 ml. per animal
of protamine sulphate, the dye being dissolved in I ml. of distilled water. Mice
received the same concentration of toluidine blue in the following doses: 0-8 ml.
on the first, 0-6 ml. on the second, 0-4 ml. from the third day, and-in addition
0-1 ml. per animal ofprotamine sulphate.
The combined preparation T4 contained 10 mg. of toluidine blue, 10 mg. of
thionine and 10 mg. of ammonium chloride per ml. of distilled water. The reason
for choosing these substances will be explained in the discussion. Rats were given
1 ml. per animal per 100 g. body weight, while mice received 0-4 ml. per animal
per 20 g. bodyweight ofthispreparation. This combination contained noprotamine
sulphate.
The preparation Tll proved to be highly toxic and therefore not suitable for
our experiments. It contained 20 mg. of toluidine blue, 10 mg. of thionine and
20 mg. of ammonium chloride per ml. of distilled water. As mentioned above,
we also tested a few other combinations. These either produced no effect or were
exceedingly toxic. The parenteral introduction of dyes, resulted in unsuccessful
experiments.
RESULTS
Toluidine blue' applied in a final concentration of lOy/ml. in the in vitro
experiments, either immediately inhibited the growth of the examined tumours,
oi did so in a very short time. The proliferation of tumour cells in the control
cultures seemed to be especially intensive and conspicuous in the case of C3H
and Ehrlich tumours. Where the fluid containing toluidine blue was added to
the cultures immediately after the explantation, only a few sporadic migrating
cells appeared and these contained the dye in the form of coarse granules. In
cases where the dye was applied 48 hours after the explantation, there was no
difference between the growth of the test and control cultures until after the addi-
tion of the dye. Then isolated granules in the cells of the test cultures filled with
the dye and showed metachroma8ia (purple). It should be noted that the growtli
of the cultures stopped forthwith so that-as regards growth-the picture seen
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A day after the application ofthe dye, it was still very finely distributed in some
cells, while in others it appeared as coarse particles as were observed in cultures
that had been treated immediately after explantation. No further growth could
be observed even 48 hours after the treatment, while the controls continued to
grow vigorously. It was at this time that the cells began to disintegrate in the
treatedcultures, aprocess which wascompleted 96 hours afterthesingle treatment.
The binding of the dye in the cells is irreversible. If the culture is normally
fed 24 hours after the first (and only) treatment and if also the subsequent wash-
ings are similar, prohferation will never occur again.
Toluidine blue in a final concentration of 1 y/ml. gave less obvious results than
the higher concentration. Only I or 2 granules were seen in the cells 24 hours
after the treatment, a.nd the tumour continued-to grow, although less intensively
than in the control cultures. The accumulation of granules became more pro-
nounced 72 hours after the treatment ; cellular disintegration began 96 hours
after the first and 48 hours after the second treatment, to become complete by
the end of the period of observation.
With oneexception, none oftheorgans enumeratedintheparagraph on method
took up toluidine blue. This exception was the thymus. Like tumour cells, the
cells of this organ-the epithelial membrane and the thymocytes-took up
toluidine blue and disintegrated sub tly.
It should be noted that inhibition of growth by the dye was always more
pronounced in the case of carcinomas than in that of sarcomas.
Results ofheparin inhibition in in vivo experiments are tabulated (Tables I to
XII). The first experiments in connection with Gue'rin's tumour were per-
formed with large doses added to the food. Seeing that this method, while being
efficacious, did not aRow of the administration ofprecise doses we began adminis-
tration by gastric tube. We took care, in our further experiments, to begin
TABLE I.-Rats Inoculated with Gue'rin Tumour Subcutaneously
Treatment begun 8 days after inoculation
Average
Number Dura- weight Standard Average
of tion tumour deviation meta-
Sex aniirnals Treatment (days) (g.) (g.) stasis Observation
F. 3 Control 26-13 ±2-4 3- 3
F. 5 Tol. blue 13 12-0 1-5 0-62 Regionally onlv.
50 mg-/day
in food
TABLE II.-Rats Inoculated with Gue'rin Tumour Subcutaneously
Treatment begun 48 hours after inoculation
Average
Number Dura- weight Standard Average
of tion tumour deviation meta-
Sex animals Treatment (days) (g.) (g.) stasis Observation
F. 5 Control 4-44 1-0 187 mg.
F. 2 Tol. blue 23 8- 1 M 1-42 250 Toxic phenomenon.
10 mg./day
F. 2 T4 23 O- 085 0-012
F. 3 T5 23 0-115 0-01811
G. CSABA, TH. ACS, CECILIA HORVATH AND ESZTER KAPA 370
TABLE III.-RaMInoculated with Gue'rin Tumour Subcutaneously
Treatment begun 13 days after inoculation
Average
Number Dura- weight Standard
of tion tumour deviation Inhibition
Sex animals Treatment (days) (g.) - (g.) - M)
M. . 4 . Control . 8- 72 1-68 .
M. . 6 . T5 7 . 6-64 1-2 24- 2 .
Observation
TABLE IV.-Rats Inoculated with Gucfrin Tumour Subcutaneously
Treatment begun 19 days after inoculation
Average
Number Dura- weight Standard Average
of tion tumour deviation meta-
Sex animals Treatment (days) (g.) (g.) stasis Observation
M. 2 Control 18-15 3-2 9-25 Abdominal cavity
filled with meta-
stasis.
M. 2 T5 7 5-85 1-8 2-65 Metastasis region-
ally only.
TABLE V.-Rats Inoculated with Gucfrin Tumour Subcutaneously
Treatment begun 28 days after inoculation
Average
Number Dura- weight Standard Average
of tion tumour deviation meta-
Sex animals Treatment (days) (g.) (g.) stasis
F. . 3 . Control 14-1 1-63 . 1-5
F. . 5 . Ts 7 . 5-3 0- 74 . 3-0
Inhibition
62-4
TABLE VI.-MiceInoculatedwith 0-05ml.ofEhrlichAscites TumourSubcutaneously
Treatment begun 24 hours after inoculation
Average
weight
Duration tumour
(days) (g-) Observations
3- 8
1-89
17 1-88 Dose toxic ; only 7 animals alive at
examination.
17 1-46 Dose strongly toxic ; only 3 animals
alive at examination.
17 1-83 Dose strongly toxic ; only 3 anianals
alive at examination.
Number
of
Sex animals Treatment
F. - 10 . Control
M. . B 9 .
F. 10 . Tol. blue
25 mg./day
+prot. sulph.
0
- I ml./day
M. . 20 . Ditto
M. - 20 . Tol. blue
25 mg./day
TABLEVII.-Mice Inoculatedwith 0-I ml.ofEhrlichA86te8Tumour
Subcutaneowly
Treatment begun 9 days after inoculation
Average
Number Dura- weight Standard
of tion tumour deviation Inhibition
Sex animals Treatment (days) (g.) (g.) M) Observation
M. 8 Control 3-41 0.63
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TABLEVIII.-Mice In-oculated with 0-2 ml. ofEhrlich Ascites Tumout-
Subcutaneously
Treatment begun 12 days after inoculation
Average
Dura- weight Standard
tion tumour deviation Inhibition
(days) (g.) (g.) M)
1-7 0.37 .
7 . 0-91 . 0-14 . 46-5 .
Nurnber
of
Sex animals
M. . 4
M. - 31
Treatment
Control
T4
Observation
TABLE IX.-Mice Inoculated with 0-1 ml. ofEhrlich Ascites Tumour
Intraperitoneally
Treatment begun 24 hours after inoculation
Amount
Dura- of
tion ascites
(days) (MI-)
3- 73 .
8 2- 78 .
Number
of
aniimals
Cell count
in I ml.
of ascites
99,980
92,800
Average
cell count
per mouse
373,104 .
258,104 .
Sex Treatment Observation
Three mice died.
Six mice died during
treatment ; no as-
cites in 2 mice.
M. . I0 . Control
M. . 10 . Tol. blue
0-4 mg.
+prot.
0
- I ml./day
M. . 10 . T40
- 8 ml.,
then 0
- 4 ml.
5
8
. 1- 5 . 114,600
TABLE X.-Mice Inoculated with 0-1 ml. o Ehrlich Ascites Tumour
Subcutaneously
Treatment begun simultaneously with inoculation
Average
Dura- weight
tion of tumour
Treatment (days) (g.)
Control 1.0
Tr, bound to 10 . 0-43 .
polyvynil
pyrolidone
Number
of
Sex animals
M. . 4
M. . 3
Standard
deviation Inhibition
(g.) M)
0-25 .
0-05 57
Observation
Two out of5 animals
died.
TABLE XI.-Mice Inoculated with Crocker S. 180 Subcutaneously
Treatment begun 10 days after inoculation
Average
Dura- weight Standard
tion of tumour deviation Inhibition
Treatment (days) (g.) (g.) M) Observation
Control 3-0 O- 7
r,, 7 . 1-52 . 0-52 49
- 5 . Three mice died dur.
ing process of feed-
ing.
Number
of
animals
13 . (
10 . I
Sex
M. .
M. .372
I 11
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TABLE XII.-Rat8 Inoculated with Yo8hida Tumour Subcutaneou8ly
Treatment begun 4 days after inoculation
Average
Number Dura- weight of Standard
of tion tumour deviation Inhibition
Sex animals Treatment (days) (g.) (g.) M Observation
M. and 10 Control 9.6 2
- 7
F.
Ditto 10 T4 7 5-5 1-35 42
- 7 Double dose on Ist
day.
10 T5 7 5-04 1-58 47- 0 Double dose of tol.
blue on Ist day.
treatment at different times, i.e. to obtain tumours with different degrees of
vitality. Figures of measurements, percentage of inhibition (wherever such
calculations were deemed to be justified by the number ofanimals) are indicated
in the tables; special observations are contained in a separate column.
Ehrlich ascites tumours were transplanted partly through the subcutaneous
andpartlythrough the intraperitoneal route. As has been mentioned, the purpose
oflow dosage was alonger survival ofthe animals.
Only a few groups were inoculated with Crocker S. 180 and Yoshida tumours
because results obtained in these cases were in perfect agreement with those
observed in connection with the other two kinds of tumours and also because the
number of animals in the particular groups seemed to suffice for adequate con-
clusions.
DISCUSSION
It was suggested in our previous publication that heparinoids may promote
neoplastic growth or that they may even be regarded as causative agents. Our
present experiments with heparin inhibitors throw a much sharper light upon
the role played bypolysaccharides.
It was proved by these experiments that even extremely low concentrations
(10-5g) of toluidine blue are capable ofinhibiting tumour growth and destroying
tumour cells in tissue cultures. Apart from this, it was shown-a fact of great
theoretical importance-that what happens in the ceRs is not a mere storage
oftoluidineblue, followedby removal byphyagocytes, but thebinding ofheparin,
a substance which is essential for the prohferation of the tumour cells. That this
is so is borne out by the fact that the dye shows metachromasia in the cells.
The balance of the experimental results aRows the conclusion that heparin is
synthesized by and utifized for the growth of malignant tumour cells. There
are, therefore, three alternatives open for us if we want to stop tumour growth
in vivo:
1. The binding of some cytotoxic substance to glucuronic acid or heparinoid:
its selective accumulation in the tumour cells should lead to their destruction.
2. The suppression of the organism's heparinoid substances with the conse-
quent inhibition of tumour growth.
3. A combination of I and 2, i.e. binding of the organism's own heparinoids,
especially oftheheparin which circulates in theblood, followedby theintroductionEFFECT OF HEPARIN INHIBITORS ON TUMOUR GROWTH 373
into the organism of heparinoids bound to a cytotoxic substance for which-on
account of the bound condition of the organism's own heparinoids-the affinity
of the tumour has increased.
Seeing that method 1 requires chemical operations that will be performed at
a later date, we began the examination of method 2, little suspecting that, by
doing so, we were to arrive at method 3, which then proved the most useful.
Results assembled in the tables make it clear that thebinding oftheheparinoid
substances strongly inhibits tumour growth. The percentage of inhibition is
usually about 45 per cent but reached in one case as much as 62-4 per cent (Table
V).
The potency of the inhibitory effect seems to depend on the rate ofgrowth of
each particular tumour, the time between tumour inoculation and the beginning oftreatment, and on the size ofthe tumour at this time. The nature ofthe tumour
does not appear to have a decisive influence on the strength of the effect, for
high values ofinhibition were obtained with every kind oftumour. We concluded
from ourexperiments that the best results could be expected if(1) treatment were
started immediately after the implantation of the tumour ; (2) slowly-growing
tumours were treated ; (3) the treatment were protracted.
We feel justified in claiming that our method, elaborated upon the basis of
theoretical considerations, yields satisfactory results in the case oftransplantable
tumours. It seems nevertheless necessary to discuss afewproblemswhich influence
the success of the treatment.
it is, first of all, very important that adequate doses be used. We observed
that the growth of the tumours did not begin to decrease immediately after the
treatment: it required 6-7 days for the animals to become saturated with the
dye. It was then that proliferation slowed or stopped and necrosis occurred.
Why is combined treatment more satisfactory than the other methods?
Neither toluidine blue (in non-toxic doses) nor protamine sulphate alone produce inhibition, while their combined application never failed to give satisfaction.
This raises the theoretical possibility that the essential point of the experiments
was morethanthesimplebinding ofheparinoidsubstances,namelythecombination
of methods I and 2. Experiments performed on rabbits (unpubhshed) have
shown that protamine sulphate is capable of strongly diminishing the heparin level of the blood for a period of 6-10 hours. The absorption of toluidine blue
is slower; this was administered perorally and not parenterally as the protamine sulphate. It is, hence, safe to assumethat, during the time ofabsorption, toluidine
blue does not-or only to a negligible extent-combine with the heparinoids of
the blood so that the dye is much more bound in the tissues. This would mean
that, after some time, the heparinoids of the tissues-including those around the
tui-lours-become bound to toluidine blue. The binding is very strong. It is, on
the otherhand, conceivable that aslong as theheparinoid substances ofthe blood
are bound by protamine sulphate, the tumours are' able to take up only those
heparinoids which are bound by toluidine blue. Provided it is true that toludine
blue accumulatedinthe cellsproduces a toxiceffect-andtheresults ofexperiments with tissue cultures confirm this assumption-all that actually happens is that
we are binding the organism's own heparinoids to a cytotoxic agent by means of
a biological procedure so that, circulating heparinoids being bound, the affinity of tumours for those heparinoid substances which are bound by toluidine blue
and situated in their immediate vicinity becomes more pronounced.374
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The question arises here: why ik; there such a great amount oftoluidine-blue-
bound heparinoids around the tumours? The answer is simple enough. The
number of mast cells increases in the neighbourhood of tumours (Asboe-Hansen,
1954; Asboe-Hansen, Levi and Wegelius, 1957; Cramer and Simpson, 1944;
Csaba, T6rb and Kiss, 1959 ; Koenig, 1955 ; Lascane, 1958) ; these cells contain
heparinoid substances which combine with toluidine blue. The affinity of the
mast cells for heparin-binding substances is very strong, perhaps stronger even
thanthat oftumour cells ; hence, ifwerequire that there should remain a sufficient
amount ofheparinoids for the tumour cells beyond what has been bound by the
mast cells, the doses used in the treatment must be adequate, and-equally-the
duration ofthe treatment itself must be long enough. Since the uptake ofhepari-
noids by the mast cells weakens the tissue barrier which helps to prevent tumour
growth, doses must be such as to damage not only the mast cells but the tumour
cells as well.
It may be presumed that the reasons why the effect ofdyes does not manifest
itself until the 6th or 7th day following treatment is that this time is needed for
the organism to acquire sufficient toluidine-bound heparinoid as to enable the
tumour to utilize this material.
Another form of treatment tested by us was the combined administration of
toluidine blue, thionine and ammonium chloride. We were led by the foRowing
considerations indoing so: (1) Thionine, too, combines withheparinoids, although
not quite asspecifically as toluidine blue. As it is less toxic it can be wellemployed
together with toluidine blue without increasing the toxicity of the latter. (2) A
histological observation was our second reason : we found that a reduction of
thepH valueduring the process ofstaining with toluidine bluehelped to make the
staining of mast cells more specific. This induced us to use ammonium chloride
for acidification in vivo, and the result proved to be satisfactory.
The objection might be raised that the tumour-reducing effect of heparin inhibitors is due to a general intoxication of the organism produced by these
substances. We think that their specific action is well proved by. the electivity observed in the course of experiments with tissue cultures, further by the fact
that we succeeded in inhibiting tumours in living animals without any sign of
a general intoxication ; and-finally-by the fact that the administration of
easily tolerated doses of the two substances (protamine sulphate and toluidine
blue) proved to be more effective than either ofthem administered independently in toxic doses.
Our experiments have thus furnished evidence to show that tumours utilize
or sy-nthesize heparinoid substances required for their growth. Led by such
EXPLANATION OF PLATE
Fie.. l'-C3H-culture 72 hours after explantation and 24 hours after normalfeeding. Control.
Unstained. x 75.
FIG. 2.-C3H-culture placed in a liquid medium containing 10 y/ml. of toluidine blue immedi-
ately after explantation and fed with the same fluid after 48 hours. The photgraph was
taken 72 hours after explantation. Accumulation of metachromatic toluidine blue observ-
able in cells. Unstained. x 75.
FIG. 3'-C3H-cWture, 72 hours after explantation and 24 hours after feeding with toluidine
blue in a final concentration of 10 y/ml. Many metachromatic granules of toluidine blue
observable in cells. Unstained. x 75.BRITISII J-017.11NAL OF CANCER. Vol. XIV, No. 2.
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thleoretical considerations we succeeded in elaborating a niethod for the inhibition
of tumour growth which has proved successful in animal experiments. The sub-
stances employed by us are antimetabolites rather than cytostatic substances.
That this is true is shown by the fact that cytostatic substances are known to
affect quickly-dividing tumour cells in the first place, while our method produces
a more marked effect if cell proliferation is slow. Far from being inconvenient,
this feature of our method is decidedly advantageous if we remember that-apart
from haemoblastoses tumours in human subjects are frequently slower growing
than transplantable animal tumours.
SUMMARY
Relying on the evidence ofin vitro and in vivo experiments the authors conclude
that tumours require heparinoid substances for their growth, and describe new
possibilities for the inhibition of tumour growth. Theoretical considerations have
led to the elaboration of a method by which it is possible to check the proliferation
of transplantable tumour cells in about 45 per cent of the test cases. These
theoretical considerations, substantiated by experimental results, open up a
fresh path to new therapeutic experiments.
The authors received valuable assistance in their experiments from the staff of
the United Works of Pharmaceutical Dietetic Products, Budapest, for which they
want to express gratitude.
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